Structure of Cenicriviroc
CAS No.: 497223-25-3
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Cenicriviroc is an oral, dual CCR2/CCR5 antagonist, and displays potent anti-inflammatory and aninfective activity.
Synonyms: TBR-652; TAK-652; CVC
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 497223-25-3 |
Formula : | C41H52N4O4S |
M.W : | 696.94 |
SMILES Code : | O=C(/C1=C/C2=CC(C3=CC=C(OCCOCCCC)C=C3)=CC=C2N(CC(C)C)CCC1)NC4=CC=C([S@](CC5=CN=CN5CCC)=O)C=C4 |
Synonyms : |
TBR-652; TAK-652; CVC
|
MDL No. : | MFCD28502076 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
Bone marrow-derived macrophages | 10nM, 20nM or 100nM | 6 hours | To evaluate the effect of CVC on LPS-induced inflammatory response in macrophages. 100nM CVC significantly inhibited LPS-induced TNFα and IL-6 release. | PMC6393202 |
Mouse primary hepatocytes | 10nM, 20nM or 100nM | 24 hours | To evaluate the effect of CVC on CCL2-induced hepatocyte steatosis. CVC down-regulated the fatty acid synthesis gene Fasn and up-regulated the fatty acid oxidation genes Acox-1, Pgc1α, and Ucp-2. | PMC6393202 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Mice | Acute sclerosing cholangitis model | Subcutaneous injection | 15 mg/kg body weight | Once daily for 5 days | Evaluate the effect of CVC on monocyte/macrophage recruitment, liver injury, and fibrosis | PMC6098983 |
Mice | Alcoholic liver disease model | Subcutaneous injection | 15mg/kg body weight | Once daily for 6 weeks (prevention cohort) or the last 3 weeks (treatment cohort) | To evaluate the preventive and therapeutic effects of CVC on alcoholic liver disease. CVC significantly reduced alcohol-induced ALT elevation, liver steatosis, inflammation and fibrosis markers, and decreased macrophage infiltration and the proportion of proinflammatory Ly6CHi macrophages. | PMC6393202 |
Mice | CPI-hepatitis model | Oral administration in drinking water | 100 mg/kg/day | Continuous administration | Prevention and treatment of CPI-hepatitis by inhibiting CCR2+ monocyte recruitment to the liver, reducing CD8+ T cell activation and liver injury | PMC11002390 |
Mice | Traumatic brain injury model | Oral gavage | 100 mg/kg | Twice daily for 24 hours | Significantly ameliorated injury-induced sequelae in the aged TBI animals | PMC4835854 |
C57BL/6J female mice | Chronic alcohol feeding model | Subcutaneous injection | 15 mg/kg body weight | Daily for 6 weeks (prevention cohort) or 3 weeks (treatment cohort) | CVC treatment abrogated ethanol-induced recruitment of peripheral macrophages and partially reversed microglia activation. Furthermore, CVC treatment decreased alcohol-mediated expression of inflammatory markers. | PMC7547498 |
C57BL/6 mice | CCl4-induced liver fibrosis model | Intraperitoneal injection | 15 mg/kg body weight | Preventive model: 4 doses of CVC and 2 doses of CCl4 per week for 6 weeks; Treatment model: 3 weeks of CCl4 followed by 4 doses of CVC and 2 doses of CCl4 per week for another 3 weeks | CVC alleviates liver fibrosis by inhibiting hepatic accumulation of FSCN1+ macrophages and HERC6+ neutrophils and restoring the immune cell landscape | PMC10197881 |
Rats and mice | Bile duct ligated (BDL) rats and Mdr2 (Abcb4)−/− mice | Gavage | 50 mg/kg/day | Once daily for 14 days (rats) or 4 weeks (mice) | To evaluate the therapeutic effects of CVC alone or in combination with atRA on cholestatic liver injury. Results showed that the combination of CVC with atRA significantly reduced liver to body weight ratio, bile acid pool size, plasma liver enzymes, bilirubin, liver necrosis and fibrosis. | PMC6032984 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03059446 | Nonalcoholic Steatohepatitis|L... More >>iver Cirrhosis|Non-alcoholic Fatty Liver Disease Less << | PHASE2 | TERMINATED | 2021-01-05 | Digestive Health Specialists o... More >>f the Southeast - Dothan, Dothan, Alabama, 36305, United States|Mayo Clinic Hospital, Phoenix, Arizona, 85054, United States|Adobe Clinical Research, LLC, Tucson, Arizona, 85712, United States|Franco Felizarta, MDv, Bakersfield, California, 93301, United States|University of California, San Diego (UCSD), La Jolla, California, 92037, United States|Inland Empire Liver Foundation, Rialto, California, 92377, United States|University of California, San Diego (UCSD) - Medical Center, San Diego, California, 92093, United States|Quest Clinical Research, San Francisco, California, 94115, United States|Upland Clinical Research, Upland, California, 91786, United States|Island View Gastroenterology Associates, Ventura, California, 93003, United States|University of Miami - Schiff Center for Liver Diseases, Miami, Florida, 33136, United States|Advanced Medical Research, Port Orange, Florida, 32127, United States|Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital, Tampa, Florida, 33606, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, 52242, United States|Kansas Medical Clinic PA, Topeka, Kansas, 66606, United States|Delta Research Partners, Llc, Bastrop, Louisiana, 71220, United States|Tandem Clinical Research LLC, Marrero, Louisiana, 70072, United States|Tulane University Medical Center, New Orleans, Louisiana, 70112, United States|Mercy Medical Center - Baltimore, Maryland, Baltimore, Maryland, 21202, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Minnesota Gastroenterology, P.A., Saint Paul, Minnesota, 55114, United States|Digestive Health Specialists, Tupelo, Mississippi, 38801, United States|University of Buffalo - Erie County Medical Center, Buffalo, New York, 14215, United States|Carolinas Medical Center, Charlotte, North Carolina, 28204, United States|Duke University Medical Center (DUMC), Durham, North Carolina, 27710, United States|Wake Research Associates, LLC - Raleigh, Raleigh, North Carolina, 27612, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, 27103, United States|Consultants for Clinical Research - Cincinnati, Cincinnati, Ohio, 45249, United States|Options Health Research, LLC, Tulsa, Oklahoma, 74104, United States|ClinSearch LLC, Chattanooga, Tennessee, 37421, United States|Gastro One, Germantown, Tennessee, 38138, United States|Digestive Health Research, Lebanon, Tennessee, 37090, United States|The University of Texas - Health Science Center & Medical School at Houston, Houston, Texas, 77030, United States|The Texas Liver Institute, San Antonio, Texas, 78215, United States|University of Utah, Salt Lake City, Utah, 84132, United States|Virginia Commonwealth University Medical College of Virginia, Richmond, Virginia, 23249, United States|Virginia Mason Medical Center, Seattle, Washington, 98101, United States|Swedish Medical Center, Seattle, Washington, 98104, United States|Royal Brisbane Hospital and Women's Hospital, Herston, Queensland, 4029, Australia|Central Adelaide Local Health Network Inc - Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Monash Medical Centre, Clayton, Victoria, 3168, Australia|Austin Health, Heidelberg, Victoria, 3084, Australia|UCL Saint Luc Bruxelles, Brussel, 1200, Belgium|University Hospital Erasmus (Brussels), Bruxelles, 1070, Belgium|Antwerp University Hospital (UZA), Edegem, 2650, Belgium|CHU Angers, Angers Cedex 09, 49933, France|Hopital Saint Antoine, Paris, 75012, France|Purpan CHU Toulouse, Toulouse, cedex 9, 31059, France|Uniklinik RWTH Aachen, Aachen, 52074, Germany|Charite - University Hospital Berlin - Campus Virchow - Hospital, Berlin, 13353, Germany|Universitaetsklinikum Hamburg-Eppendorf - I. Medizinische Klinik und Poliklinik, Hamburg, 20246, Germany|Universitaetsklinikum Heidelberg - Innere Medizin IV, Heidelberg, 69120, Germany|Uniklinik Koeln, Poliklinik fuer Endokrinologie, Diabetologie und Praeventivmedizin (ZEDP), Koeln, 50937, Germany|Eugastro GmbH, Leipzig, 4103, Germany|University Hospital Giessen and Marburg GmbH, Marburg, 35043, Germany|Prince of Wales Hospital, Shatin, Hong Kong, Hong Kong|Policlinico S. Orsola-Malpighi, Bologna, 40138, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milano, 20122, Italy|AOU Policlinico Paolo Giaccone di Palermo, Palermo, 90127, Italy|ID Clinic, Myslowice, 41-400, Poland|Centrum Badan Klinicznych Piotr Napora Lekarze Sp. p., Wroclaw, 50-349, Poland|Fundacion de Investigacion de Diego, San Juan, 927, Puerto Rico|Hospital Universitario Vall d'Hebron, Barcelona, 8022, Spain|Hospital de la Santa Creu i Sant Pau Barcelona, Barcelona, 8026, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|Nottingham NHS Treatment Centre, Nottingham, NG7 2UH, United Kingdom|Queen Alexandra Hospital, Portsmouth, PO6 3LY, United Kingdom Less << |
NCT03376841 | Hepatic Impairment | PHASE1 | COMPLETED | 2017-12-17 | Clinical Pharmacology of Miami... More >>, Miami, Florida, 33014, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.43mL 0.29mL 0.14mL |
7.17mL 1.43mL 0.72mL |
14.35mL 2.87mL 1.43mL |
Tags: Cenicriviroc | TAK-652 | TBR-652 | TAK652 | TAK 652 | TBR652 | TBR 652 | TBR-652 | CCR | HIV | CC chemokine receptor | Human immunodeficiency virus | CCR2/CCR5 antagonist | CCR2 antagonist | CCR5 antagonist | 497223-25-3
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL